Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, Ambrx Biopharma, EYPT, BBIO, ACLX, and represent 49.75% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: Ambrx Biopharma (+$160M), EYPT (+$66M), ALXO (+$38M), AUTL (+$33M), Cargo Therapeutics (+$27M), SNDX (+$25M), Korro Bio (+$25M), Abivax SA F (+$23M), HARP (+$22M), MLTX (+$21M).
- Started 11 new stock positions in LNTH, SNDX, Praxis Precision Medicines I, EDIT, Abivax SA F, Neurogene, Ambrx Biopharma, VYNE, Korro Bio, Cargo Therapeutics. SYRE.
- Reduced shares in these 10 stocks: Ambrx Biopharma (-$114M), APLS (-$82M), GPCR (-$53M), BBIO (-$53M), CBAY (-$48M), CABA (-$44M), OLMA (-$29M), ACLX (-$25M), KRTX (-$24M), ERAS (-$21M).
- Sold out of its positions in Ambrx Biopharma, RNA, CABA, COGT, ELVN, ERAS, KRTX, ORTX, Praxis Precision Medicines I, GPCR. VIGL, ZNTL.
- Cormorant Asset Management was a net seller of stock by $-74M.
- Cormorant Asset Management has $2.1B in assets under management (AUM), dropping by 22.14%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 48 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 24.5 | $513M | +4% | 8.5M | 60.39 |
|
Ambrx Biopharma | 7.6 | $160M | NEW | 11M | 14.24 |
|
Eyepoint Pharmaceuticals Com New (EYPT) | 6.7 | $140M | +88% | 6.0M | 23.11 |
|
Bridgebio Pharma (BBIO) | 6.4 | $135M | -28% | 3.3M | 40.37 |
|
Arcellx Common Stock (ACLX) | 4.5 | $94M | -20% | 1.7M | 55.50 |
|
Rayzebio (RYZB) | 3.6 | $75M | +2% | 1.2M | 62.17 |
|
Biomea Fusion (BMEA) | 2.5 | $52M | 3.6M | 14.52 |
|
|
Immunovant (IMVT) | 2.3 | $49M | -4% | 1.2M | 42.13 |
|
Alpine Immune Sciences (ALPN) | 2.3 | $49M | +34% | 2.6M | 19.06 |
|
Pharvaris N V (PHVS) | 2.3 | $48M | +25% | 1.7M | 28.05 |
|
Alx Oncology Hldgs (ALXO) | 2.2 | $47M | +413% | 3.1M | 14.89 |
|
Tarsus Pharmaceuticals (TARS) | 2.1 | $45M | -15% | 2.2M | 20.25 |
|
Cymabay Therapeutics (CBAY) | 2.0 | $43M | -53% | 1.8M | 23.62 |
|
Vaxcyte (PCVX) | 2.0 | $42M | 665k | 62.80 |
|
|
Crinetics Pharmaceuticals In (CRNX) | 2.0 | $41M | +4% | 1.2M | 35.58 |
|
Apellis Pharmaceuticals (APLS) | 1.8 | $37M | -68% | 625k | 59.86 |
|
Marinus Pharmaceuticals Com New (MRNS) | 1.7 | $35M | +23% | 3.3M | 10.87 |
|
Autolus Therapeutics Spon Ads (AUTL) | 1.7 | $35M | +1289% | 5.5M | 6.44 |
|
Olema Pharmaceuticals (OLMA) | 1.6 | $35M | -45% | 2.5M | 14.03 |
|
Immuneering Corp Class A Com (IMRX) | 1.5 | $31M | 4.2M | 7.35 |
|
|
Edgewise Therapeutics (EWTX) | 1.3 | $28M | -13% | 2.6M | 10.94 |
|
Aerovate Therapeutics (AVTE) | 1.3 | $27M | -22% | 1.2M | 22.63 |
|
Cargo Therapeutics | 1.3 | $27M | NEW | 1.2M | 23.15 |
|
Syndax Pharmaceuticals (SNDX) | 1.2 | $25M | NEW | 1.2M | 21.61 |
|
Korro Bio | 1.2 | $25M | NEW | 529k | 47.93 |
|
Rhythm Pharmaceuticals (RYTM) | 1.2 | $25M | -35% | 550k | 45.97 |
|
Abivax Sa Sponsored Ads | 1.1 | $23M | NEW | 2.1M | 10.70 |
|
Harpoon Therapeutics Com New (HARP) | 1.1 | $23M | +4245% | 2.3M | 9.60 |
|
Spyre Therapeutics Com New (SYRE) | 1.0 | $20M | NEW | 937k | 21.52 |
|
Insmed Com Par $.01 (INSM) | 0.9 | $18M | 575k | 30.99 |
|
|
Ideaya Biosciences (IDYA) | 0.8 | $16M | -25% | 450k | 35.58 |
|
Axonics Modulation Technolog (AXNX) | 0.7 | $16M | 250k | 62.23 |
|
|
Neurogene | 0.7 | $15M | NEW | 746k | 19.38 |
|
Longboard Pharmaceuticals In (LBPH) | 0.7 | $14M | 2.4M | 6.03 |
|
|
Praxis Precision Medicines I Com New | 0.7 | $14M | NEW | 633k | 22.28 |
|
Rocket Pharmaceuticals (RCKT) | 0.6 | $14M | 450k | 29.97 |
|
|
Rapt Therapeutics (RAPT) | 0.6 | $12M | +52% | 497k | 24.85 |
|
Disc Medicine (IRON) | 0.3 | $7.2M | -44% | 125k | 57.76 |
|
Stoke Therapeutics (STOK) | 0.3 | $5.7M | 1.1M | 5.26 |
|
|
Editas Medicine Put Option (EDIT) | 0.2 | $5.1M | NEW | 500k | 10.13 |
|
Verve Therapeutics (VERV) | 0.2 | $4.9M | 350k | 13.94 |
|
|
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.2 | $4.7M | NEW | 75k | 62.00 |
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $4.5M | 562k | 7.96 |
|
|
Biohaven (BHVN) | 0.2 | $3.5M | 82k | 42.80 |
|
|
Gh Research Ordinary Shares (GHRS) | 0.2 | $3.4M | 593k | 5.80 |
|
|
Vyne Therapeutics (VYNE) | 0.2 | $3.2M | NEW | 1.4M | 2.33 |
|
Bioatla (BCAB) | 0.1 | $2.9M | 1.2M | 2.46 |
|
|
Neumora Therapeutics (NMRA) | 0.1 | $1.6M | 92k | 17.05 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022
- Cormorant Asset Management 2022 Q1 filed May 16, 2022
- Cormorant Asset Management 2021 Q4 filed Feb. 14, 2022
- Cormorant Asset Management 2021 Q3 filed Nov. 15, 2021
- Cormorant Asset Management 2021 Q2 filed Aug. 16, 2021
- Cormorant Asset Management 2021 Q1 filed May 17, 2021
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020
- Cormorant Asset Management 2020 Q1 filed May 15, 2020